(Q33794917)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

title

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

Grant McArthur

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

author name string

D Handolias

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

A L Hamilton

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

R Salemi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

A Tan

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

K Moodie

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

L Kerr

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

language of work or name

English

0 references

publication date

6 April 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

30 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

volume

102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

page(s)

1219-1223

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/sj.bjc.6605635

30 January 2020

exact match

0 references

cites work

Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Major response to imatinib mesylate in KIT-mutated melanoma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Somatic activation of KIT in distinct subtypes of melanoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Kit as a human oncogenic tyrosine kinase

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Cerebral relapse of metastatic gastrointestinal stromal tumor during treatment with imatinib mesylate: case report

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

Central nervous system blastic crisis in chronic myeloid leukemia on imatinib mesylate therapy: a case report.

28 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605635

KIT gene mutations and copy number in melanoma subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605635

Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605635

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605635

Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605635

Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605635

Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605635

Imatinib mesylate has limited activity against the central nervous system involvement of Philadelphia chromosome-positive acute lymphoblastic leukaemia due to poor penetration into cerebrospinal fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJC.6605635

Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2856012

The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20372153

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Sorafenib Inhibits the Imatinib-Resistant KITT670I Gatekeeper Mutation in Gastrointestinal Stromal Tumor

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20372153

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/SJ.BJC.6605635

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

30 January 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20372153%20AND%20SRC:MED&resulttype=core&format=json

30 January 2020

1 reference